Endothelial stem cell therapy (Regen BioPharma)

N/A

Report date: 2025/09/29 17:45:03

Base Information

Drug NameEndothelial stem cell therapy (Regen BioPharma)

Drug Alias NameHemaXellerateHemaXellerate IAplastic anemia stem cell therapy (Regen BioPharma)Autologous stromal vascular fraction cells (Regen BioPharma)Personalized Stem Cells therapy (Regen BioPharma)

ClassificationCell and gene therapy > Cell therapy > Source of cells > Adipose-derivedCell and gene therapy > Cell therapy > Stem cell therapy

Mechanisms of ActionBone marrow cells stimulantsStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsAnemia, Aplastic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRegen Biopharma

China Registration ClassN/A

Develop Information

Active CompaniesRegen Biopharma

Inactive CompaniesN/A

Active IndicationsAnemia, Aplastic

Inactive IndicationsN/A

Other Information

ATC CodeN/A